Meta buys Manus to scale AI agents across its platform

    Meta faces China probe over acquisition of AI agent startup Manus

    Chinese officials are reviewing Meta’s $2 billion acquisition of AI startup Manus for possible technology control violations, FT reported on Tuesday. Sopa Images | Lightrocket | Getty Images China said Thursday it will investigate Meta‘s $2 billion acquisition of artificial intelligence startup Manus to assess its compliance with export control laws. Meta acquired Singapore-based Manus last month…

    Read More
    Mark Cooper, Investment Partner at the UK Office for Investment, delivering his keynote presentation.

      UK unveils decade-long growth vision to Hong Kong investors

      [The content of this article has been produced by our advertising partner.] The UK set out its growth agenda in Hong Kong at the inaugural UK Investment Conference, where the country’s industrial strategy and sector opportunities in finance, life sciences, clean energy and advanced manufacturing were presented.  Hosted by the British Consulate-General Hong Kong on…

      Read More
      The LEAD framework teaching methodology has earned Professor Wu both the Faculty Teaching Excellence Awards 2022-23 (left) and the University Education Award 2024 (right)

        Leading students through open doors

        [The content of this article has been produced by our advertising partner.] Although her academic journey began at two of the world’s most prestigious institutions – first as an undergraduate at Peking University, then as a doctoral researcher at Stanford University – Professor Willow Wu has never allowed herself to be confined by the proverbial…

        Read More
        The ‘biology winter’ thaws: why investors are piling into Hong Kong’s biotech IPOs

          The ‘biology winter’ thaws: why investors are piling into Hong Kong’s biotech IPOs

          Hong Kong’s biotech fundraising momentum is expected to extend into 2026, as licensing deals and strong post-initial public offering (IPO) trading last year persuaded investors that China’s drug developers are worth backing again – even before they generate revenue. “Chinese innovation drugs expanding into overseas markets have become the industry mainstream, indicating the domestic innovation…

          Read More